TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean levels of TAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement with positive and negative OPs detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of subgingival calculus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body image dissatisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: prosthetic motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: implant exposure rates
Endpoint domain: Adverse events/effects
Primary endpoint: end-systolic diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percent ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain Regulation 1 postvaccination score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Regulation 2 postvaccination score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FTC/TDF mutations detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of locoregional relapse
Endpoint domain: Mortality/survival
Primary endpoint: risk of distant relapse
Endpoint domain: Mortality/survival
Primary endpoint: Rate of antipsychotic polypharmacy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean projected cost of additional antipsychotics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recurrent deep-vein thromboses and pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Peak FEV1 effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Duration of FEV1 effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUC for FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in PaO2, PaCO2, FEV1 and SaO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: maximum uroflow rate (Qmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Popliteal vein peak systolic velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ankle circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calf circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compartment syndrome incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Healing complication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Skin temperature in the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival correlated with p53 expression
Endpoint domain: Mortality/survival
Primary endpoint: Resolution of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hip bone mineral density decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Vitamin D level improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Freedom from any ventricular tachyarrhythmia (VT or VF)
Endpoint domain: Mortality/survival
Primary endpoint: Graft patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of stenosis in vein grafts
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical asthma score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of resolution of MetS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Likelihood of development of MetS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Need for open decortication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ER use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Q‐tility scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: duration of health states
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to bowel movement (TBM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Beta-blocker tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Fluoride concentration in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Aortic Valve Area (AVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximal muscular isometric strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak stress LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Response (OR) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of CD4+ decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Development of AIDS
Endpoint domain: Mortality/survival
Primary endpoint: 30-day all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: serum creatinine changes at 72 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean drop in fasting blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Final synkinesis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained virological response (negative HCV-RNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of women not delivering within 48 hours
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of augmentation with Syntocinon
Endpoint domain: Adverse events/effects
Primary endpoint: Complications associated with intra‐amniotic prostaglandin
Endpoint domain: Adverse events/effects
Primary endpoint: change in gait velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of reduction from moderate ascites to mild ascites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MenC baby rabbit complement titers ≥1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antipolyribosylribitol phosphate (Hib) IgG concentrations ≥ 1.0 μg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antipertussis toxin IgG geometric mean concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Spondyloarthritis Research Consortium of Canada MRI index for measuring spinal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospital length of stay after transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total hospital costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: cumulative primary patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: composite of cognitive test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: average daily mood ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: total bleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIQ (Fibromyalgia Impact Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Global cognition improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to complete 5 sit-to-stands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite measure of functional and cognitive status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-year risk of multiple sclerosis
Endpoint domain: Mortality/survival
Primary endpoint: Parkinson Disease Questionnaire 39 mobility score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral palsy incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Elevation of hepatic enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year overall cumulative implant survival rate
Endpoint domain: Mortality/survival
Primary endpoint: cumulative survival rate for prostheses
Endpoint domain: Mortality/survival
Primary endpoint: overall average marginal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-term healthcare use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: long-term healthcare use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mortality associated with elevated V(D)/V(T)
Endpoint domain: Mortality/survival
Primary endpoint: Reaction time in monetary incentive delay task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores measured in MADRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores measured in HRSD‐17
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent reduction in weekly stress urinary incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with changes in urinary incontinence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of moderate-to-severe vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Visualization of features of mandibular ORN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior-posterior extent of the lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual search/selective attention improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Superficial skin closure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: CVP during PLR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔSV during PLR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for PLR predicting volume responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall pain intensity above lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall pain frequency above lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunization levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum cortisol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clinical Attachment Level (AL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year progression-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: CCF (Cardiac Compression Fraction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of symptomatic venous thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: Improvement rates for acute PE and DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of NVC in affected trigeminal nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: lesion recurrence
Endpoint domain: Mortality/survival
Primary endpoint: reexcision rate due to positive margins
Endpoint domain: Adverse events/effects
Primary endpoint: width of excisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Coronary Blood Flow (CBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean open horizontal probing depth reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: >50% vertical defect fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to discharge
Endpoint domain: Mortality/survival
Primary endpoint: high-sensitive C-reactive protein (hs-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain QLQ-C30 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Amount of total bacteria in tongue coating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial amounts in dental plaque samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p-Cu levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CuZn-SOD activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportions of S.mutans to S.sanguinis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postepidural backache
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in melanin index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in MASI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Erythema at TA-applied site
Endpoint domain: Adverse events/effects
Primary endpoint: retinal flicker sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in substance use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of sensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Microvessel Density (MVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of transient LES relaxations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Upgrade in Gleason score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Success at achieving oral feeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: O2 production in PMN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prolongation of functional life span of PMN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of apoptosis in PMN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Platelet recovery to baseline levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neutrophil nadir severity after chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Parkinsonism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive fluctuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Systematised delusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Risk of developing muscle TMDs and temporomandibular joint pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Presence of articular TMDs associated with chronic arthralgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of responders displaying a 2-point versus a 1-point improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response longevity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication of head lice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Myocardial perfusion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Expression of key sarcoplasmic reticulum Ca(2+) cycling and stretch response genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reductions in overall psychological symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in overall domain‐specific sense of control
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: higher scores on a measure of spiritual experiences
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fugl-Meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Achieving the blood pressure goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative risk of moderate dyskariosis or worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean superior retinal capillary blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak systolic velocity in the central retinal artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: casual PG level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VAS scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SKFS scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blockade of VAS 'any drug effect' response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of apnea
Endpoint domain: Adverse events/effects
Primary endpoint: Serum total alkaline phosphatase (ALP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone-specific ALP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IL-1beta and TNF-alpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Implant loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Necessity of retreatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of adverse events and adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability and safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to treatment failure (TTF)
Endpoint domain: Mortality/survival
Primary endpoint: hamstring injury incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in total number of gluten sensitivity symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the concentration-time curve (AUC(τ,ss)) of empagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration (C(max,ss)) of empagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Subjective acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: peri-operative morbidity and mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: resection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: future liver remnant hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with best practice in advance care planning policy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean change from baseline to week 10 on the PARS severity for GAD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: EVD revisions due to dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: complete remission of tinnitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lessening of tinnitus intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjectively agreeable change of noise characteristics
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rotavirus IgA seroconversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: winter episodes of URTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: winter days of illness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue